Moderna stock jumps on $2.6 billion note sale and fresh buy call
Published on 08/28/2026 at 20:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. (US60770K1034) stock is moving on August 28, 2026 after the company priced $2.6 billion of convertible notes due 2032 and Argus lifted its rating to Buy with a $180 target. Shares last traded at $136.48 in one real-time estimate, with a market cap of $57.00 billion and a 5-day change of -4.69%.
Deal terms matter
The notes price the company at a conversion value of about $210.58 per share, a 47.5% premium to the August 27, 2026 close of $142.77. That structure gives investors a cleaner read on dilution, funding flexibility and the valuation that debt buyers were willing to accept.
The same market snapshot showed a 50-day moving average of $75.62 and a 200-day moving average of $59.17, which leaves the stock well above both trend lines. The 12-month range in the same report ran from $22.28 to $176.66, a wide band that reflects the speed of this year's rerating.
Quarterly numbers still matter
Moderna's latest quarterly report, released on July 31, 2026, showed EPS of -$1.97 versus consensus at -$2.03 and revenue of $145.0 million versus $102.93 million expected. Revenue also rose 2.1% from the same quarter a year earlier, while net margin stayed negative at 141.43%.
For investors, the combination of a smaller-than-expected loss, a sharper top line and a fresh capital raise is more important than the headline move alone. Analysts now show a $106.62 average target across 22 analysts, which sits below the latest trading level and below Argus' $180 call.
Pipeline backdrop
Moderna's mRNA platform still centers on vaccines and therapeutics, with its COVID-19 shot remaining the flagship commercial product. The broader pipeline and the updated seasonal vaccine approval on August 27, 2026 add context to the capital markets move, but the stock's short-term path is still being set by financing, execution and sentiment.
More on Moderna stock: the shares are trading on Nasdaq under MRNA and remain tied to the market's view of how quickly sales can scale beyond pandemic-era demand.
Price and setup
As of August 28, 2026, the stock was last quoted at $136.48 in the cited real-time estimate, with a prior close of $142.77 and market cap of $57.00 billion. That keeps Moderna far above its 50-day and 200-day averages, but still below the 12-month high of $176.66.
Company facts
Company: Moderna Inc.
ISIN: US60770K1034
Ticker: MRNA
Exchange: Nasdaq
Price (as of August 28, 2026, 10:05 a.m. ET): $136.48 USD
Market cap: $57.00 billion
Sector / Industry: Healthcare / Biotechnology
Index membership: Nasdaq-100
More on Moderna stock
Moderna's main commercial product is its mRNA-based COVID-19 vaccine, which remains the clearest product reference point for the company's revenue base and regulatory news flow.
